
A newly published two-year study involving 446 patients with post-traumatic stress disorder (PTSD) has found that prescribed medical cannabis use was associated with significant improvements in trauma-related symptoms, anxiety, sleep quality, and overall health-related quality of life. Published November 12, 2026, in the peer-reviewed journal Psychopharmacology, the research examined patients enrolled in the United Kingdom Medical Cannabis Registry and represents one of the longer prospective investigations into cannabis-based medicines for PTSD. Researchers documented a substantial decline in average PTSD symptom scores during the observation period, with the greatest improvements appearing within the first month of treatment.
The findings add new long-term information to an area of cannabis medicine that continues to attract considerable interest from patients, healthcare professionals, and researchers. Although participants reported improvements across several measures, the investigators emphasized that the observational study cannot establish whether cannabis directly caused those changes. Most participants had previously used marijuana, a substantial proportion did not complete the final assessments, and no placebo or untreated comparison group was included. Nevertheless, the research offers valuable insight into the experiences of patients receiving prescribed cannabis products for a psychiatric condition that can be difficult to manage with conventional treatment alone.
Researchers Follow 446 PTSD Patients for Up to Two Years
The investigation was conducted by researchers affiliated with Imperial College London, Curaleaf Clinic, and other participating institutions. The study, titled Cannabis-Based Medicinal Products for Post-Traumatic Stress Disorder: A Two-Year Prospective Analysis from the UK Medical Cannabis Registry, examined medical records and patient-reported outcomes collected through a national registry managed by Curaleaf Clinic. Participants had confirmed PTSD diagnoses and received prescriptions for cannabis-based medicinal products after conventional licensed treatments had failed to provide sufficient symptom relief. Prescribing decisions involved specialist psychiatric evaluation and multidisciplinary review, reflecting the controlled medical cannabis framework used in the United Kingdom.
Researchers assessed patient outcomes before treatment and at one, three, six, 12, 18, and 24 months. The average participant was approximately 39 years old, and nearly 61% were men. Anxiety and depression were common accompanying conditions, reflecting the complex psychological difficulties frequently experienced by people living with PTSD. The study also recorded cannabis formulations, prescribed cannabinoid doses, previous marijuana exposure, and reported adverse events. Unlike a randomized clinical trial, participants received individualized treatment under real-world medical conditions, allowing investigators to observe outcomes over an extended period without imposing standardized experimental dosing.
PTSD Symptom Scores Decline Nearly 38 Percent
One of the study’s central findings involved changes in the Impact of Events Scale-Revised (IES-R), a questionnaire used to evaluate psychological distress associated with traumatic experiences. The assessment examines symptoms such as intrusive memories, avoidance behaviors, and heightened emotional or physiological reactions. Before treatment, participants had an average IES-R score of 59.58, indicating substantial trauma-related distress. By the 24-month assessment, the estimated average score had declined to 36.91, representing an approximately 38% reduction. Researchers reported statistically significant improvements at every follow-up interval compared with baseline, although the later averages relied heavily on estimates for missing responses.
Improvements were observed across the questionnaire’s intrusion, avoidance, and hyperarousal categories. These symptoms can have a considerable effect on daily functioning, relationships, employment, and emotional stability. Intrusive memories may cause individuals to repeatedly experience distressing aspects of past trauma, while hyperarousal can contribute to persistent alertness, irritability, and difficulty relaxing. Despite the lower average scores, approximately 55% of participants still met the IES-R screening threshold associated with PTSD at the two-year mark. This distinction is important because reduced symptom severity does not necessarily indicate recovery, and the questionnaire alone cannot establish whether someone continues to meet formal diagnostic criteria.
Anxiety, Sleep Quality and Everyday Functioning Also Improve
Beyond trauma-specific symptoms, the research identified favorable changes in several measures of psychological and physical well-being. Anxiety was evaluated using the Generalized Anxiety Disorder-7 questionnaire, while sleep quality was assessed using a standardized single-item rating scale. Participants reported improvements in both areas throughout the observation period. According to the researchers’ statistical estimates, 72.2% achieved a clinically meaningful reduction in anxiety scores by 24 months, while 53.4% achieved a clinically meaningful improvement in sleep quality. These figures provide additional detail beyond simple statistical significance, although they remain affected by the study’s substantial missing follow-up data.
Health-related quality of life was measured using the EQ-5D-5L questionnaire, which examines mobility, self-care, usual activities, pain, and anxiety or depression. Participants reported improvements in several dimensions, particularly their ability to perform everyday activities, their experiences with pain and discomfort, and their psychological well-being. These outcomes are relevant because PTSD often affects considerably more than trauma-related memories. Persistent sleep disturbances, difficulty concentrating, chronic stress, and reduced participation in ordinary activities can combine to undermine quality of life. The study suggests that some patients receiving medical cannabis perceived improvements across multiple areas of functioning, although other ongoing treatments or changes in personal circumstances may also have influenced those reports.
Most Reported Improvements Appeared During the First Month
An especially interesting finding was the timing of symptom changes. Researchers observed that the largest improvement between consecutive assessments occurred during the first month after medical cannabis treatment began. Average scores then remained relatively stable across later follow-up periods rather than showing continuous improvement throughout the full two years. This pattern raises questions about whether early changes reflect a direct response to cannabinoids, changes in sleep or anxiety, expectations surrounding a new prescription, or other factors. The observational design cannot distinguish between these possible explanations.
The apparent durability of improvement also depended on how researchers handled missing assessments. Under the main statistical approach, which estimated unavailable responses using multiple imputation, average PTSD scores remained substantially below baseline at 24 months. A more conservative analysis that carried forward participants’ original scores when later data were missing produced a different trajectory. Under that approach, the average IES-R score declined initially but subsequently moved back toward baseline, reaching 49.91 after two years. Both analyses showed improvement relative to the starting point, but the difference illustrates why the long-term findings should be interpreted cautiously rather than as definitive evidence of sustained treatment effectiveness.
Previous Cannabis Experience Influenced the Study Population
Most participants were not encountering cannabis for the first time. Of the 446 patients, 335 individuals, or approximately 75%, reported actively using marijuana before beginning their prescribed treatment. Another 73 participants were former users, while only 38 had never previously consumed cannabis. This distribution matters because individuals already familiar with marijuana may have developed expectations about its benefits, greater tolerance to certain effects, or established patterns of use. It also means the results may not accurately represent what would happen if cannabis-naive patients with PTSD began treatment under otherwise similar circumstances.
Researchers nevertheless identified improvements among participants with differing cannabis histories. In the cannabis-naive subgroup, average PTSD symptom scores declined from 61.43 to 38.17 over the observation period, based on the study’s statistical analysis. Participants already using marijuana also reported lower symptom scores after receiving medical cannabis prescriptions. However, the relatively small number of first-time users limits the conclusions that can be drawn about people without prior exposure. Additional research involving larger cannabis-naive populations would help establish whether previous experience influences treatment response, adverse effects, or long-term outcomes.
THC-Dominant Products Were Commonly Prescribed
The study examined several medical cannabis formulations, including dried flower, cannabis oils, capsules, and other preparations. Dried cannabis flower was the most frequently prescribed product at the beginning of treatment, accounting for approximately 52% of prescriptions. At 24 months, dried flower alone remained the most common category, while combinations of flower and cannabis oil were also widely prescribed. Patients generally vaporized prescribed flower products and used oils sublingually. These arrangements reflect specialized medical prescribing practices rather than a standardized cannabis regimen that could be applied to all PTSD patients.
A notable observation involved increasing prescribed THC exposure. Median daily THC prescriptions rose from 20 milligrams at baseline to approximately 214.5 milligrams by 24 months, while median CBD prescriptions reached 22 milligrams daily. These figures describe prescribed amounts, not necessarily the quantities patients actually consumed, and should not be interpreted as recommended doses. Researchers suggested that individualized adjustments, changes in product selection, and possible cannabinoid tolerance could help explain the increase. Importantly, higher THC dose categories did not demonstrate a clear association with greater improvement in PTSD symptoms. The substantial escalation in prescribed THC exposure reinforces the need for research examining effective dosing, dependence risk, cognitive effects, and long-term safety.
Researchers Document Hundreds of Adverse Events
The safety analysis identified 75 patients, representing 16.82% of the study population, who reported at least one adverse event. Altogether, researchers documented 578 events, including 244 classified as mild, 249 as moderate, 83 as severe, and two categorized as life-threatening or disabling. Insomnia and fatigue were the most frequently recorded complaints. The two most serious events involved pharyngitis and diabetic ketoacidosis, but investigators could not determine whether either was related to cannabis treatment. Because the registry did not systematically distinguish newly emerging symptoms from preexisting medical conditions, the adverse-event data cannot establish the true frequency of treatment-caused harm.
Patients without previous cannabis exposure appeared more likely to report adverse events than those already using marijuana before receiving prescriptions. This observation is consistent with the possibility that prior exposure influences tolerance to some cannabinoid effects, although it does not establish that cannabis becomes harmless with repeated use. The researchers also acknowledged that adverse effects may have been missed when participants discontinued treatment or stopped completing assessments. Long-term cannabis use can involve additional concerns, including dependence, withdrawal symptoms, impaired attention, and interactions with medications. As a result, the reported adverse-event rate should not be interpreted as proof that prolonged cannabinoid treatment is safe for everyone with PTSD.
Important Study Limitations Prevent Conclusions About Effectiveness
Despite the substantial number of participants and extended observation period, the investigation has several limitations. Most importantly, it was an uncontrolled prospective case series rather than a randomized, placebo-controlled clinical trial. Without a comparison group, researchers cannot determine whether improvements resulted from cannabis itself, concurrent psychotherapy, conventional medications, natural changes in PTSD severity, or patients’ expectations about treatment. Participants were permitted to continue other PTSD therapies, but information about those treatments was not systematically collected. Recruitment through a private medical cannabis clinic also introduced potential selection bias because participants were actively seeking cannabis treatment and may have been more likely to believe it could help.
Incomplete follow-up data created another major challenge. Only 158 participants completed the PTSD symptom questionnaire at 24 months, leaving approximately 64.6% of the final responses to be statistically estimated. Different assumptions about those missing responses produced meaningfully different results, limiting confidence in the reported long-term changes. Several investigators also disclosed professional relationships with Curaleaf Clinic or Curaleaf International, organizations involved in medical cannabis services. Such relationships do not invalidate the findings, but they reinforce the value of independent replication. The research contributes useful observational evidence while leaving the central question of whether medical cannabis directly treats PTSD unresolved.
Earlier Cannabis and PTSD Research Has Produced Mixed Results
The latest findings build on previous analyses of the UK Medical Cannabis Registry. Earlier research followed 162 patients for six months and subsequently 269 patients for up to 18 months, reporting improvements in trauma-related symptoms and other measures of well-being. The new investigation expands the registry cohort to 446 participants and extends observation to two years, although the earlier participants were included within the larger sample. Research involving other patient registries has also documented favorable outcomes, particularly for sleep disturbances, nightmares, and anxiety. However, results from uncontrolled studies cannot carry the same evidentiary weight as improvements demonstrated against a suitable comparison group.
More rigorous research has not consistently confirmed a benefit for PTSD itself. A randomized trial examining smoked cannabis preparations in military veterans found no significant advantage over placebo during its controlled phase. A major systematic review published in The Lancet Psychiatry in March 2026 examined 54 randomized trials involving 2,477 participants across multiple mental health and substance use conditions and found insufficient evidence supporting cannabinoids as treatments for PTSD and several other psychiatric disorders. A separate 2026 evidence review also found low-certainty evidence showing no clinically significant improvement in overall PTSD symptom severity compared with controls. These findings do not rule out benefits for particular symptoms or patient subgroups, but they demonstrate why promising observational results require further controlled testing.
What the Findings Mean for Medical Cannabis and PTSD Treatment
PTSD can develop after exposure to traumatic experiences such as military combat, sexual violence, serious accidents, assault, or other life-threatening events. The condition can involve recurring nightmares, intrusive memories, avoidance, negative mood changes, and persistent physiological arousal. Established treatments include trauma-focused psychotherapies such as prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing. Certain antidepressant medications can also be used when clinically appropriate. Cannabis research has attracted attention partly because some patients report incomplete relief from conventional treatment or experience persistent symptoms despite receiving professional care.
The latest UK findings may encourage further investigation into whether particular cannabinoid formulations can complement established PTSD treatments, especially for patients struggling with sleep disturbances or severe anxiety. However, improvements in individual symptoms should not be confused with evidence that cannabis treats the underlying disorder. The U.S. Department of Veterans Affairs and Department of Defense clinical practice guideline continues to recommend against cannabis or cannabis derivatives as PTSD treatment because reliable evidence of effectiveness remains insufficient and safety concerns persist. Patients considering cannabinoid products should discuss potential benefits, psychiatric risks, and drug interactions with qualified healthcare professionals rather than replacing evidence-based PTSD care.
Future Clinical Trials Will Determine Whether Cannabis Can Treat PTSD
Researchers are increasingly interested in how cannabinoids influence the endocannabinoid system, which participates in stress regulation, emotional processing, and fear-related learning. Investigations involving THC, CBD, and pharmaceutical cannabinoid preparations may help clarify whether different compounds influence specific PTSD symptoms through distinct mechanisms. Future studies will need to compare treatments against placebo, evaluate standardized formulations, include meaningful numbers of cannabis-naive participants, and accurately measure both actual cannabinoid consumption and concurrent psychiatric treatment. Longer follow-up periods will also be necessary to determine whether any improvements persist without increasing doses or creating additional risks.
The November 2026 study provides an important addition to the developing medical cannabis literature by documenting patient experiences over a two-year period. Its central finding is that people receiving prescribed cannabis-based medicines for PTSD reported improvements in trauma-related distress, anxiety, sleep, and quality of life, with most apparent changes occurring early in treatment. Yet substantial missing data and the absence of a control group mean the study cannot establish therapeutic effectiveness. For researchers, clinicians, and patients, the findings offer a reason to investigate further rather than a definitive treatment recommendation. Whether medical cannabis can provide reliable, lasting relief from PTSD remains an important question that future randomized clinical trials must answer.






